TY - JOUR
T1 - Quantification of Phosphonate Drugs by 1H-31P HSQC Shows That Rats Are Better Models of Primate Drug Exposure than Mice
AU - Barekatain, Yasaman
AU - Khadka, Sunada
AU - Harris, Kristen
AU - Delacerda, Jorge
AU - Yan, Victoria C.
AU - Chen, Ko Chien
AU - Pham, Cong Dat
AU - Uddin, Md Nasir
AU - Avritcher, Rony
AU - Eisenberg, Eugene J.
AU - Kalluri, Raghu
AU - Millward, Steven W.
AU - Muller, Florian
N1 - Funding Information:
The following grants were used to support this work: the U.S. National Institutes of Health (NIH) grant 1R01CA231509-01A1 to S.W.M., the American Cancer Society Research Scholar Award RSG-15-145-01-CDD to F.L.M., the Andrew Sabin Family Foundation Fellows Award to F.L.M., the Brockman Medical Research Foundation to F.L.M., the Marine Rose Foundation to F.L.M., and Uncle Kory Foundation funds to F.M.L. Y.B. was supported by the CPRIT Training Award (RP210028), Dr. John J. Kopchick Fellowship, and Schissler Foundation. S.K. was supported by the CPRIT Training Award (RP210028) and Larry Deaven Fellowship. K.H. was supported by PCCSM. K.C. and S.K. were supported, in part, by NIH R01 CA225955 to R. DePinho. The authors thank Dr. Raghu Kalluri’s lab members for their help and support and Dr. Kumaralal K. Kaluarachchi, the manager of the NMR facility at U.T.M.D. Anderson, and Dr. Clemens Anklin from Bruker BioSpin. The authors also acknowledge Dr. Dimitra K. Georgiou and Kenisha Arthur for their help. Illustrations are created with BioRender.com.
Publisher Copyright:
© 2022 American Chemical Society. All rights reserved.
PY - 2022/7/19
Y1 - 2022/7/19
N2 - The phosphonate group is a key pharmacophore in many antiviral, antimicrobial, and antineoplastic drugs. Due to its high polarity and short retention time, detecting and quantifying such phosphonate-containing drugs with LC/MS-based methods are challenging and require derivatization with hazardous reagents. Given the emerging importance of phosphonate-containing drugs, developing a practical, accessible, and safe method for their quantitation in pharmacokinetics (PK) studies is desirable. NMR-based methods are often employed in drug discovery but are seldom used for compound quantitation in PK studies. Here, we show that proton-phosphorous (1H-31P) heteronuclear single quantum correlation (HSQC) NMR allows for the quantitation of the phosphonate-containing enolase inhibitor HEX in plasma and tissues at micromolar concentrations. Although mice were shown to rapidly clear HEX from circulation (over 95% in <1 h), the plasma half-life of HEX was more than 1 h in rats and nonhuman primates. This slower clearance rate affords a significantly higher exposure of HEX in rat models compared to that in mouse models while maintaining a favorable safety profile. Similar results were observed for the phosphonate-containing antibiotic, fosfomycin. Our study demonstrates the applicability of the 1H-31P HSQC method to quantify phosphonate-containing drugs in complex biological samples and illustrates an important limitation of mice as preclinical model species for phosphonate-containing drugs.
AB - The phosphonate group is a key pharmacophore in many antiviral, antimicrobial, and antineoplastic drugs. Due to its high polarity and short retention time, detecting and quantifying such phosphonate-containing drugs with LC/MS-based methods are challenging and require derivatization with hazardous reagents. Given the emerging importance of phosphonate-containing drugs, developing a practical, accessible, and safe method for their quantitation in pharmacokinetics (PK) studies is desirable. NMR-based methods are often employed in drug discovery but are seldom used for compound quantitation in PK studies. Here, we show that proton-phosphorous (1H-31P) heteronuclear single quantum correlation (HSQC) NMR allows for the quantitation of the phosphonate-containing enolase inhibitor HEX in plasma and tissues at micromolar concentrations. Although mice were shown to rapidly clear HEX from circulation (over 95% in <1 h), the plasma half-life of HEX was more than 1 h in rats and nonhuman primates. This slower clearance rate affords a significantly higher exposure of HEX in rat models compared to that in mouse models while maintaining a favorable safety profile. Similar results were observed for the phosphonate-containing antibiotic, fosfomycin. Our study demonstrates the applicability of the 1H-31P HSQC method to quantify phosphonate-containing drugs in complex biological samples and illustrates an important limitation of mice as preclinical model species for phosphonate-containing drugs.
UR - http://www.scopus.com/inward/record.url?scp=85135892715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135892715&partnerID=8YFLogxK
U2 - 10.1021/acs.analchem.2c00553
DO - 10.1021/acs.analchem.2c00553
M3 - Article
C2 - 35792073
AN - SCOPUS:85135892715
SN - 0003-2700
VL - 94
SP - 10045
EP - 10053
JO - Analytical Chemistry
JF - Analytical Chemistry
IS - 28
ER -